STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Thymosin Beta-4

Also known as

Tβ4 · TB4 · TB-4 · Thymosin β4 · Timbetasin (INN) · full-sequence TB4 · full-length thymosin beta-4 · RGN-259 (0.1% ophthalmic research formulation) · TMSB4X gene product (endogenous context) · synthetic Tβ4 (clinical IV / wound-gel programs)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Some talk Mixed SubQ / IM / IV / Topical / Ophthalmic Healing & repair

Mixed — research-chem injectables are treated as systemic soft-tissue repair; clinical programs also use topical wound gels and ophthalmic drops.

What people say Full thymosin beta-4 is a 43-amino-acid actin-binding peptide. TB-500 labeling is inconsistent, so full Tβ4, a short fragment and an unspecified vial must not share evidence by name alone. Doses people talk about
Community full-Tβ4 weekly-load talk~5–10 mg total per week

A repeated community total tied to claimed full-sequence product, with daily-versus-biweekly disagreement and no controlled musculoskeletal comparison.

TB-500-style pattern applied to claimed full TB4~2–2.5 mg SubQ twice weekly

Preserved 4–6-week loading talk followed by about 2–2.5 mg once weekly; identity and bioequivalence are unresolved.

One BPC co-use account0.75 mg SubQ daily

The poster's product identity was unclear; the later elbow report was confounded by BPC and the shoulder received cortisone.

Human Phase I IV cohorts42, 140, 420 or 1260 mg IV

In each healthy-volunteer dose cohort, participants received placebo or active synthetic full Tβ4 as a single dose and then the same assigned regimen daily for 14 days; safety/PK research, not a sports-injury regimen.

These rows are separated by claimed molecular identity, route and research setting; none authorizes transfer to an ambiguously labeled TB-500 vial.

Half-life & effect duration

Half-life in the body
  • Full Tβ4 · IV studiesAbout 0.95–2.1 hours, increasing across studied dose groups
Felt duration people report
  • One combination-use accountAn elbow improvement reported months later
  • After one doseNo consistent felt duration reported
Timing context & sources
How it may feel The clearest reviewed outcome was not a per-dose sensation: one BPC co-user later said the elbow did well, while the shoulder also received cortisone. Product identity and attribution remained unresolved.
Cycles people discuss Community material mixes daily low-milligram full-Tβ4 talk with 4–6-week twice-weekly TB-500-style loading and later maintenance. Topical, ocular and IV studies are different formulations and schedules. Timing Morning versus evening and training-day versus rest-day preferences circulate in community accounts, without a controlled comparison. These timing preferences do not establish SubQ kinetics or transfer between full Tβ4 and TB-500 products. Stacks BPC-157 is the dominant co-use discussion; GHK-Cu and KPV appear in GLOW/KLOW contexts, while PT, deload and sleep are major co-drivers. These are not proven synergistic combinations. Watch for Source / identity risk: Mislabeling (TB-500 sold as full TB4 or vice versa), underdosed vials, contamination, and fake COAs are core gray-market hazards. Mass spectrometry / sequence beats marketing names.
Related
TB-500BPC-157GHK-CuKPV

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

Mean plasma half-life increased from about 0.95 to 2.1 hours across high-dose IV cohorts.

Forty healthy volunteers were enrolled across four cohorts and received placebo or synthetic full Tβ4 at 42, 140, 420 or 1260 mg IV; the primary abstract reports dose-proportional exposure and increasing half-life, while a full-text secondary paper reports 0.95, 1.2, 1.9 and 2.1 hours.

High-dose IV full-length peptide does not establish SubQ kinetics for injury-market products, identity of a TB-500 vial, fragment kinetics or tissue-effect duration.

Felt duration people report

The inspected longitudinal report supplied a months-later injury outcome but no onset, offset or per-dose felt window.

The poster started 0.75 mg daily with BPC, later said the elbow did well and disclosed a cortisone injection for the shoulder; the product's full-Tβ4 versus TB-500 identity was not established.

Single self-report with two injuries, BPC co-use, cortisone treatment and unresolved product identity; outcome timing cannot be attributed to one molecule.

  • TB-500 THYMOSIN BETA 4 Dosage (opens in a new tab)Complete visible archived thread inspected. Johnny7448 described a 3000 mcg/mL compounded product charted at 0.25 mL SubQ daily for 20 days, then began 0.75 mg daily with BPC; months later the same author said the elbow did well and the shoulder received cortisone. Replies disagreed about full Tβ4 versus fragment identity and schedule.Unverified product identity, BPC co-use, two injury sites and later cortisone prevent attribution; commenters' molecular and half-life assertions are not treated as measured facts.

What people say 12

  • Soft-tissue recovery: Users report multi-week faster bounce-back from strains, overuse stiffness, and training niggles vs rest alone — often in dual stacks. forum
  • Mobility / ROM: Common claim of better range or less connective-tissue “tight” feel over a loading block, frequently with PT. forum
  • Tendons & joints: Stubborn tendon/joint irritation threads often pair full TB4 or TB-500 with BPC-157; single-agent credit is hard to isolate. forum
  • vs TB-500 community claim: Some argue full 43-aa TB4 is “more complete” (extra domains beyond LKKTETQ, including N-terminal Ac-SDKP-related talk) and often charted at higher weekly mg — there are no head-to-head MSK RCTs of research-chem full TB4 vs TB-500. forumtrial
  • Stack confound: Outcomes frequently posted under BPC + TB4/TB-500, GLOW (BPC+TB+GHK-Cu), or KLOW (+KPV) — solo full-TB4 credit is muddy. forum
  • Hair / skin minority: Occasional hair-growth or dermal-quality anecdotes bleed over from Tβ4 animal/skin literature; far thinner than injury talk. animalanecdote
  • Human MSK honesty: Large modern RCTs of gray-market full-TB4 injectables for sports soft-tissue injury are sparse; clinic and forum logs dominate that use case. trialforum
  • Dermal wounds (human programs): Phase II-style topical Tβ4 gel work in venous stasis ulcers and pressure ulcers reported accelerated healing windows in responders (e.g. mid-dose interest around 0.03% in venous-ulcer dose-finding discussion; 0.01–0.1% gel arms studied for ~84 days in venous-stasis programs). trial
  • Eyes (RGN-259): 0.1% Tβ4 ophthalmic solution studied for dry-eye endpoints (e.g. discomfort and corneal staining reductions in Phase II NCT01387347 discussion) and neurotrophic keratopathy (complete healing signals in small cohorts and later Phase III–style reports). trial
  • Cardiac / ischemia research: Preclinical cardioprotection and early human development interest (AMI / reperfusion narratives); Phase I IV safety supported further exploration — not a gym injury protocol. animaltrial
  • Animal models: Faster wound closure, regenerative endpoints, and soft-tissue/cardiac models widely cited as the mechanism backbone. animal
  • Angiogenesis / migration lab hook: Cell-migration and blood-vessel endpoints in vitro and in animals are the standard science-blog bridge to forum injury claims. labanimal

Doses people talk about 20

  • Unit scale: Full TB4 is discussed in milligrams (or hundreds of mcg → low mg), not pure microgram culture like BPC-157 — beginners regularly mix units. forum
  • Weekly load (full TB4, common band): ~5–10 mg total per week during loading is repeatedly cited for full-sequence product talk (higher weekly mass than many TB-500 charts). forum
  • Per-shot multi-mg pattern (TB-500-style copy applied to full TB4): ~2–2.5 mg SubQ twice weekly for ~4–6 weeks (≈4–5 mg/week), then ~2–2.5 mg once weekly maintenance — the most repeated “classic” chart pattern across TB4/TB-500 threads. forum
  • Higher multi-mg loading: ~2.5–5 mg twice weekly, or weekly totals toward ~5–10 mg in acute soft-tissue threads; occasional brief front-load ~5 mg 2×/week for ~2 weeks then step-down. forum
  • Clinic frequency talk: Some integrative writeups say full TB4 3–5×/week SubQ without publishing a single universal mg figure — schedules vary by clinic. forum
  • 8-week dual-stack example (secondary writeups): BPC daily + thymosin beta-4 ~2–5 mg twice weekly SubQ near injury for ~8 weeks appears in injury-regimen discussions. forum
  • Weekly total summary (full TB4 discussion): Loading often ~4–10 mg/week depending on daily-vs-biweekly culture; maintenance often ~1–5 mg/week or “as needed.” forum
  • Wolverine concurrent BPC: BPC usually ~250–500 mcg/day SubQ (sometimes 200–500 mcg 1–2×/day) while TB4/TB-500 stays on its own multi-mg 1–2×/week (or daily low-mg full-TB4 chart). Injected separately in careful protocols; pre-mix “Wolverine blend” vials also exist. forum
  • Compounded Wolverine blend math (examples, ratios vary): Clinic marketing examples include ~5 mg BPC + ~10 mg TB per vial (≈1:2 BPC:TB by mass in that vial). Duration depends on prescribed draw — not standardized. forum
  • GLOW pre-mix math (vendor-variable): Common GLOW talk ≈ 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500/TB (70 mg total, 5:1:1). Daily small SubQ draws may deliver only ~0.3 mg TB-equivalent/day — not the same exposure as 2.5 mg 2×/week standalone. Alternate lower-copper vials (e.g. ~27/5/10) circulate. forum
  • KLOW pre-mix: Often GLOW + KPV (e.g. ~50/10/10/10 mg GHK/BPC/TB/KPV ≈ 80 mg total talk) — vendor ratios vary; do not assume solo full-TB4 charts. forum
  • Animal → human extrapolation talk (not a protocol): Rodent work often ~6 mcg/mouse IP or ~mg/kg systemic ranges; animal reviews cite preferred experimental bands roughly 2–12 mg/kg with ~6 mg/kg common in some cardiac models. Community allometric blog math sometimes lands ~5–10 mg/week human-equivalent hand-waves — treat as discussion, not validated MSK dosing. animalforum
  • Local vs systemic injection debate: Near-injury SubQ for accessible limbs vs abdomen/love-handle for “systemic” — TB lore is less dogmatic than BPC site fights; many claim systemic effect regardless of site. forum
  • IM minority: Intramuscular discussed for muscle belly injuries less often than SubQ. forum
  • vs TB-500 dose culture: TB-500 charts commonly land ~2–5 mg/week (e.g. 2–2.5 mg 2×/week load → 1×/week maintain); full-TB4 talk more often claims higher weekly mg or daily-sub-mg saturation — still not head-to-head RCT dosing science. forum
  • Identity / purity flag: Vials labeled TB-500 may not be full 43-aa Tβ4; full-TB4 charts must not be copied onto fragment products without COA/mass confirmation. Labeled mg may not equal delivered peptide. forum
  • Phase I IV (safety, not injury protocol): Synthetic Tβ4 single and 14-day multiple IV doses of 42, 140, 420, or 1260 mg in healthy volunteers were well tolerated with no dose-limiting toxicity (Ruff et al., 2010) — orders of magnitude above forum SubQ mg. trial
  • Topical wound gels (clinical): Venous stasis / pressure-ulcer programs studied gel concentrations such as 0.01%, 0.03%, 0.1% Tβ4 for multi-week courses (e.g. ~84 days in venous-stasis dose-response talk) — not DIY injectable math. trial
  • Ophthalmic (clinical): RGN-259 0.1% Tβ4 drops in dry-eye and neurotrophic keratopathy programs — clinical route, not a gym stack. trial
  • Framing: Community-, clinic-, and trial-discussed ranges only — not advice, not prescriptions, not verified product content. Research-use / educational context. forum

How it may feel 8

  • No clean per-dose feel in the inspected account: One poster began 0.75 mg daily with BPC for golf elbow and a strained shoulder, then months later said the elbow did well but the shoulder received a cortisone injection. The product's full-Tβ4 versus TB-500 identity remained unresolved. anecdote
  • Weeks 1–2: Early logs often mention less daily stiffness or “complaint noise,” not a sudden pain wipe — especially when load is also cut. forum
  • Weeks 2–3: Soft-tissue users sometimes claim first believable mobility or warm-up-pain shift if rehab is concurrent. forum
  • Weeks 3–4: Common checkpoint — clearer progress, hold course, rethink stack/ratio, or reassess diagnosis and training load. forum
  • Weeks 4–6: Typical load → maintenance decision for full TB4 and TB-500-style multi-mg schedules. forum
  • Weeks 6–8+: Many acute injury blocks wrap; chronic joint support talk may continue lower-frequency shots. forum
  • Months 2–3: Some consolidate on lower weekly totals; others stop when the acute issue settles and keep gains only if load stays smart. forum
  • No change by ~4–6 weeks: Forums generally push re-check of diagnosis, product identity (full vs fragment), sleep, and PT — not automatic mg escalations. forum

Cycles people discuss 10

  • Loading block: ~2 weeks (daily low-mg full-TB4 culture) or ~4–6 weeks (classic multi-mg 2×/week culture) of higher frequency or weekly total for acute soft-tissue goals. forum
  • Overall cycle length: ~4–8 weeks common for a first injury block; clinic writeups often ~6–8 weeks then reassess; chronic talk sometimes 8–12 weeks with lower maintenance. forum
  • After load: Drop to once weekly, twice weekly low dose, or stop when symptoms settle. forum
  • Maintenance vs stop: Low-frequency continue for “joint support,” or full stop after acute issue quiets — no consensus. forum
  • Time off: Examples include multi-week off after 6–8 on, seasonal breaks, or “1 month off per 3 months on” style cycling language in some peptide-therapy blogs; long-term continuous gray-market injectable safety is not established. forum
  • Wolverine block structure: Shared guides often pair ~4 weeks load (daily BPC + TB 2×/week) then ~4 weeks maintenance, evaluate around week 8; blend vials may run continuous clinic protocols for chronic pain talk. forum
  • GLOW / KLOW cycles: Pre-mix blogs often cite ~daily injections up to ~30 days then ≥15 days off, or 4–12 week injury windows — vendor- and clinic-dependent. forum
  • Re-runs: Common around later injury seasons, camps, or flares — still anecdotal. forum
  • Not indefinite by default: Most careful threads treat multi-mg repair peptides as blocks, not lifelong daily drugs. forum
  • Clinical topical/ocular courses: Wound gels over weeks-to-~3 months and eye-drop courses of days-to-weeks in trial protocols — separate from injectable sports cycles. trial

Timing 8

  • Short blood presence vs longer repair narrative: Forums justify non-daily multi-mg shots by “biological/repair window lasts longer than plasma” — plausible tissue-signaling story, not the same as multi-day depot PK proof for every product. forumanecdote
  • Why 1–2×/week multi-mg culture exists: Aligns with TB-500 charts; competing full-TB4 daily 500 mcg–1 mg charts argue short half-life needs more frequent tissue exposure. Both camps coexist without controlled MSK winners. forum
  • Endogenous levels: Natural serum/plasma Tβ4 is low (order of ~ng/mL; community/scientific summaries often cite roughly ~12–18 ng/mL or ~15–40 ng/mL ranges depending on source) and rises at injury sites via platelet/cellular release — biology context, not a dose recipe. trialforum
  • After last shot: Users often say mobility/recovery changes continue for days–weeks while tissue remodels — confounded by concurrent rehab. anecdote
  • Timing of day: AM vs PM, training day vs rest day preferences circulate; no controlled comparison. forum
  • With BPC schedule: Different half-life lore is exactly why dual stacks keep daily BPC + less-than-daily multi-mg TB (or daily low-mg full TB4 + daily BPC). forum
  • Plasma half-life in high-dose human IV research: Synthetic full Tβ4 showed dose-dependent mean half-lives of about 0.95, 1.2, 1.9 and 2.1 hours after 42, 140, 420 and 1260 mg IV single doses. This does not establish SubQ kinetics for gray-market products or any TB-500 fragment. trial
  • Tissue peak animal note: Some cardiac IP work reported maximal heart tissue concentrations ~2 h post-dose — used in experimental timing, not a gym protocol. animal

More on what it is 8

  • vs TB-500 (critical): Full Tβ4 is a 43-amino-acid peptide of about 4.9 kDa. Community and commercial labels use “TB-500” inconsistently for full Tβ4, the 17–23 sequence LKKTETQ, or an unspecified product, so evidence and dose talk cannot be transferred without identity proof. trialforum
  • Why people search: Injury recovery, “Wolverine” stacks, and constant label confusion where vials say TB-500 but marketing cites full-Tβ4 wound/eye trials. forum
  • Mechanism talk (forum-simplified): G-actin sequestration → cell migration; angiogenesis (VEGF-linked narratives); anti-inflammatory / NF-κB talk; anti-apoptosis and tissue-remodeling stories drawn from full-Tβ4 literature. forumanimallab
  • Research lens: Community mg charts and “Wolverine healed me” posts are discussion artifacts until identity (full 43-aa vs fragment), COA, rehab, and load management are controlled. forum
  • What it is: Naturally occurring 43-amino-acid actin-sequestering peptide (encoded by TMSB4X); synthetic full-length Tβ4 is the research/clinic molecule people mean by “full TB4,” distinct from shorter TB-500 fragments. trial
  • Clinical name: Timbetasin is the WHO-recommended INN for thymosin beta-4 in pharmaceutical programs. trial
  • Evidence posture: Stronger human signal in dermal wound gels and RGN-259 ocular programs plus Phase I IV safety than in large modern MSK injectable RCTs for sports soft-tissue injury. trial
  • What it is not: Not a steroid, not a GH secretagogue, not automatically the same product as “TB-500,” not an FDA-approved sports-injury drug, not proven continuous lifelong injectable therapy. trial

Stacks 9

  • Wolverine stack (dominant): Full TB4 or TB-500 + BPC-157 — top injury dual stack; labels blur between full molecule and fragment. Typical talk: BPC ~250–500 mcg daily + TB multi-mg 1–2×/week (or full-TB4 daily low-mg chart). forum
  • Wolverine blend vials: Pre-mixed BPC+TB in fixed ratios (e.g. ~5 mg BPC + ~10 mg TB per vial in some clinic marketing) — ratios and concentration vary; draw schedule set by provider/vendor chart. forum
  • GLOW stack: TB4/TB-500 + BPC-157 + GHK-Cu for skin + recovery crossover; common vendor vial talk 50/10/10 mg GHK/BPC/TB (ratios vary). forum
  • KLOW stack: GLOW + KPV for added anti-inflammatory narrative; common talk ~50/10/10/10 mg class totals — vendor-variable. forum
  • GH-axis add-ons: Sometimes stacked with CJC-1295 / Ipamorelin or other secretagogues for “recovery + GH” blocks — multi-agent confounded logs. forum
  • TB4 + GHK-Cu (without full GLOW branding): Repair + collagen/skin remodeling talk; GHK often charted separately (e.g. low-mg multi-weekly) when not in a pre-mix. forum
  • Inflammation extras: Occasional KPV, thymosin alpha-1, or LL-37 adjacency in advanced forums — different risk profiles. forum
  • PT / deload / sleep: Physical therapy, load management, and sleep are repeatedly credited as co-drivers of good outcomes — not optional flavor text. forum
  • What stacks are not: Not proven synergistic RCTs; more mg and more agents increase cost, identity risk, and confound interpretation. forumtrial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 10

  • Injection site: Redness, irritation, sting, or swelling — worse with poor technique, large volumes, or same-site reuse. forum
  • Mild systemic: Headache, fatigue, lethargy, or flu-like feel after multi-mg shots in a minority of logs. forumanecdote
  • Cancer / angiogenesis caution (contested): Full Tβ4 is pro-angiogenic and linked in some oncology literature to migration/metastasis markers; other work reports tumor-suppressive contexts (e.g. multiple myeloma expression discussions). Forums and clinics often advise avoiding active or recent malignancy as a precaution. No clear human evidence that research-chem injury dosing “causes cancer,” but the theoretical debate is real and unresolved. trialforum
  • Source / identity risk: Mislabeling (TB-500 sold as full TB4 or vice versa), underdosed vials, contamination, and fake COAs are core gray-market hazards. Mass spectrometry / sequence beats marketing names. forum
  • Legal / regulatory: Research-chemical and compounding status varies by jurisdiction; investigational eye/wound programs (timbetasin, RGN-259) are not authorization for forum commerce or self-experimentation. trialforum
  • Interactions: No solid systematic drug-interaction matrix in forum charts; concurrent NSAIDs, anticoagulants, immunosuppressants, or other peptides remain uncharacterized in controlled injury stacks. forum
  • Pregnancy / pediatric: Not established; avoid as a default research-community caution. forum
  • Blend confounds: GHK-Cu copper load, KPV, and multi-peptide syringes add separate irritation and handling issues beyond solo TB4. forum
  • Safety limit honesty: Favorable short-term clinical tolerability at high IV doses and topical/ocular programs does not establish long-term safety of multi-month gray-market injectable use for sports injuries. trialforum
  • Phase I IV tolerability: Ruff et al. (2010) — adverse events infrequent, mild–moderate; no dose-limiting toxicities or serious AEs across 42–1260 mg IV single and 14-day multiple dosing in healthy volunteers. Early clinical tolerability ≠ long-term gray-market SubQ sports use proof. trial

Updated: 2026-08-12

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →